PlainRecalls
FDA Drug Moderate Class II Terminated

Preferred Pharmaceuticals, Inc, Ranitidine Tablets, 150 mg, a) 30 count bottles (NDC: 68788-7388-3), b) 60 count bottles (NDC: 68788-7388-6), c) 90 count bottles (NDC: 68788-7388-9), d) 100 count bottles (NDC: 68788-7388-1)

Reported: January 29, 2020 Initiated: January 7, 2020 #D-0796-2020

Product Description

Preferred Pharmaceuticals, Inc, Ranitidine Tablets, 150 mg, a) 30 count bottles (NDC: 68788-7388-3), b) 60 count bottles (NDC: 68788-7388-6), c) 90 count bottles (NDC: 68788-7388-9), d) 100 count bottles (NDC: 68788-7388-1)

Reason for Recall

CGMP Deviations: Presence of NDMA impurity detected in product.

Details

Units Affected
221,710 tablets
Distribution
Distribution to physicians in the following states: AL, AZ, CA, FL, GA, IN, and SC
Location
Anaheim, CA

Frequently Asked Questions

What product was recalled?
Preferred Pharmaceuticals, Inc, Ranitidine Tablets, 150 mg, a) 30 count bottles (NDC: 68788-7388-3), b) 60 count bottles (NDC: 68788-7388-6), c) 90 count bottles (NDC: 68788-7388-9), d) 100 count bottles (NDC: 68788-7388-1). Recalled by Preferred Pharmaceuticals, Inc. Units affected: 221,710 tablets.
Why was this product recalled?
CGMP Deviations: Presence of NDMA impurity detected in product.
Which agency issued this recall?
This recall was issued by the FDA Drug on January 29, 2020. Severity: Moderate. Recall number: D-0796-2020.